Research programme: anti-infectives - Xellia Pharmaceuticals

Drug Profile

Research programme: anti-infectives - Xellia Pharmaceuticals

Alternative Names: XEL 1001; XEL 1002; XEL 1003; XEL 1004; XEL 1005; XEL 1007; XEL 1009

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Xellia Pharmaceuticals
  • Developer SINTEF Materials and Chemistry; Statens Serum Institut; Xellia Pharmaceuticals
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators; Cell wall inhibitors; Lipopolysaccharide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis-associated respiratory tract infections; Gram-positive infections
  • No development reported Gram-negative infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Gram-negative-infections in Norway (Parenteral)
  • 21 Dec 2015 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in Norway (Parenteral) before December 2015
  • 21 Dec 2015 Preclinical trials in Gram-positive infections in Norway (Parenteral) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top